bioRxivImmunologyPreprint
Antigenic Sensitivity of Membrane-Proximal Targeting Chimeric Antigen Receptors can be Fine-Tuned through Hinge Truncation
S. McComb, T. Nguyen, K. A. Henry, D. Bloemberg, D. Bloemberg, A. Marcil, S. Maclean, R. Gilbert, C. Gadoury, R. Pon, T. Sulea, Q. Zhu, R. D. Weeratna
Abstract
BackgroundChimeric antigen receptor (CAR) technology has revolutionized the treatment of B-cell malignancies and steady progress is being made towards CAR-immunotherapies for solid tumours. Epidermal growth factor family receptors EGFR or HER2 are commonly overexpressed in cancer and represent proven targets for CAR-T therapy; given their expression in healthy tissues it is imperative that any targeting strategy consider the potential for on-target off-tumour toxicity. MethodsHerein, we utilize high-throughput CAR screening to identify novel camelid single-domain antibody CARs (sdCARs) with high EGFR-specific CAR-T response. To optimize antigenic sensitivity of this EGFR-sdCAR, we performed progressive N-terminal truncation of the human CD8 hinge domain used as a spacer in many CAR constructs. Hinge truncation resulted in decreased CAR sensitivity to EGFR and improved selectivity for EGFR-overexpressing cells over EGFR-low target cells or healthy donor derived EGFR-positive fibroblasts. To investigate the molecular mechanism of hinge truncation, we test hinge-truncated scFv-based CARs targeting membrane proximal or membrane distal domains of EGFR-family proteins, HER2 and EGFRvIII. Finally, we proceed to test hinge variant EGFR-sdCAR functionality through in vitro and in vivo assessments in primary T cells derived from multiple donors. ResultsFor CARs targeting membrane-proximal epitopes, hinge truncation by even a single amino acid provided fine control of the antigenic sensitivity, whereas CARs targeting membrane distal domains were not sensitive to even complete hinge domain removal. Hinge-modified EGFR-sdCARs showed consistent and predictable responses in Jurkat-CAR cells and primary human CAR-T cells in vitro and in vivo. ConclusionsOverall, these results indicate that membrane-proximal epitope targeting CARs can be modified through hinge length tuning for programmable antigenic sensitivity and improved tumour selectivity. O_FIG O_LINKSMALLFIG WIDTH=196 HEIGHT=200 SRC="FIGDIR/small/360925v2_ufig1.gif" ALT="Figure 1"> View larger version (48K): org.highwire.dtl.DTLVardef@1f0db64org.highwire.dtl.DTLVardef@1d3ac43org.highwire.dtl.DTLVardef@1d270faorg.highwire.dtl.DTLVardef@f7614f_HPS_FORMAT_FIGEXP M_FIG C_FIG O_LISingle amino acid truncations of CD8-hinge domain provide precise control of CAR antigen sensitivity C_LIO_LITruncated hinge CARs show enhanced selectivity for antigen overexpressing tumour cells and decreased activity towards healthy antigen-expressing cells C_LIO_LIEpitope location is a critical factor in determining hinge sensitivity for a CAR C_LIO_LIHinge tuning can modulate CAR-T antigenic sensivity in vitro and in vivo C_LI
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Inefficient exploitation of accessory receptors reduces the sensitivity of chimeric antigen receptors.
J. Burton, J. A. Siller-Farfan, … O. Dushek·bioRxiv·Oct 26, 2021
- A CHIMERIC RECEPTOR ENABLING ANTIBODY-GUIDED RETARGETING OF CAR T- CELLS
Natasha Vinanica, J Q Yeo, … Dario Campana·bioRxiv·Apr 29, 2026
- Safety switch optimization enhances antibody-mediated elimination of CAR T cells
T. B. Shabaneh, H. F. Moffett, … M. J. Lajoie·bioRxiv·Aug 24, 2022
- Restricting CAR T Cell Trafficking Expands Targetable Antigen Space
E. A. Morales, K. A. Dietze, … T. Luetkens·bioRxiv·Feb 8, 2024
- Optimising CAR-T cell sensitivity by engineering matched extracellular sizes between CAR/antigen and CD2/CD58 adhesion complexes
Jake Burton, Jesús A. Siller‐Farfán, … Omer Dushek·bioRxiv·Jan 6, 2025
- The CD28-transmembrane domain mediates chimeric antigen receptor heterodimerization with CD28